OSLO, Norway, Oct.17, 2018 /PRNewswire/ --
FINANCIAL YEAR 2018
Quarterly Report - Q3 06.11.2018 (changed from 21.11.2018) Quarterly Report - Q4 27.02.2019
FINANCIAL YEAR 2019
Annual General meeting 25.04.2019 Quarterly Report - Q1 23.05.2019 Half-yearly Report 22.08.2019 Quarterly Report - Q3 21.11.2019
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact: IR enquiries Malene BrondbergVP Investor Relations and Corporate Communications Cell: +44-7561-431-762 Email: [email protected] International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: [email protected]
About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector---financial-calendar,c2646221
FINANCIAL YEAR 2018
Advertisement
Quarterly Report - Q3 06.11.2018 (changed from 21.11.2018) Quarterly Report - Q4 27.02.2019
FINANCIAL YEAR 2019
Annual General meeting 25.04.2019 Quarterly Report - Q1 23.05.2019 Half-yearly Report 22.08.2019 Quarterly Report - Q3 21.11.2019
Advertisement
The dates are subject to change. The time and location of the presentations will be announced in due time.
This information is published pursuant to the requirements set out in the Continuing obligations.
For further information, please contact: IR enquiries Malene BrondbergVP Investor Relations and Corporate Communications Cell: +44-7561-431-762 Email: [email protected] International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: [email protected]
About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector---financial-calendar,c2646221
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector--financial-calendar-300732564.html
SOURCE Nordic Nanovector
